Evaluation of the long-term cost-effectiveness of liraglutide therapy for @entity1 with @entity164 2 XXXX in France.

@entity1 @entity5735 @entity6 @entity16024 @entity12350 @entity164 @entity7634 @entity2449
OBJECTIVES: The present study aimed to compare the projected long-term clinical and cost implications associated with liraglutide, @entity12350 and @entity16024 in @entity1 with @entity6 failing to achieve glycemic control on @entity2449 monotherapy in France. METHODS: Clinical input data for the modeling analysis were taken from two randomized, controlled trials ( @entity5735 and LEAD-2). Long-term ( @entity1 lifetime) projections of clinical outcomes and direct costs (2013 @entity7634 ;    ) were made using a validated computer simulation model of @entity164 2 @entity6 . Costs were taken from published France-specific sources. Future costs and clinical benefits were discounted at 3% annually. Sensitivity analyses were performed. RESULTS: Liraglutide was associated with an increase in quality-adjusted life expectancy of 0.25 quality-adjusted life years (QALYs) and an increase in mean direct healthcare costs of    2558 per @entity1 compared with @entity12350 . In the comparison with @entity16024 , liraglutide was associated with an increase in quality-adjusted life expectancy of 0.23 QALYs and an increase in direct costs of    4695. Based on these estimates, liraglutide was associated with an incremental cost-effectiveness ratio (ICER) of    10,275 per QALY gained vs @entity12350 and    20,709 per QALY gained vs @entity16024 in France. CONCLUSION: Calculated ICERs for both comparisons fell below the commonly quoted willingness-to-pay threshold of    30,000 per QALY gained. Therefore, liraglutide is likely to be cost-effective vs @entity12350 and @entity16024 from a healthcare payer perspective in France.
